The ARROW study reported an ORR of 71% for pralsetinib,31 while the LIBRETTO-531 study showed an ORR of 69.4% for selpercatinib.32 These data suggest the promising potential of SY-5007 in treating RET-mutant MTC, meriting further exploration and validation in larger patient cohorts. This evidence concerns the gene RET and medullary thyroid gland carcinoma.